엘리 릴리 앤드 컴퍼니(Eli Lilly and Company)는 전 세계적으로 사람의 의약품을 연구, 개발, 상용화하는 데 전념하는 저명한 글로벌 제약 기업입니다. 치료 분야의 ...
이 글은 2026년 하반기가 시작됨에 따라 신뢰할 수 있는 배당 소득을 원하는 투자자들을 위해 수익률이 높은 3개 종목—노보 노디스크(NVO), 리얼티 인컴(O), 엔터프라이즈 프로덕츠 파트너스(EPD)—을 소개합니다. 노보 노디스크는 3.5%의 수익률을 제공하며 GLP-1 약물 부문에서 점유율을 되찾고 있는 반면, 엔터프라이즈 프로덕츠 파트너스는 중간자산(미드스트림) 에너지 부문에서 원자재 가격 노출이 낮아 5.9%의 수익률을 제공합니다. 리얼티 인컴은 REIT로서 장기간의 증가 이력을 바탕으로 매달 5%의 일관된 배당금을 지급해 소득 의존형 투자자들에게 매력적입니다.
브리스톨-마이어스 스퀴브 컴퍼니(BMY) 주식은 7월 13일에 3.07% 상승했으며, 온콜로지 및 면역학 분야에서의 긍정적 임상 데이터, 성공적인 규제 관련 이정표, 그리고 효과적인 비용 최적화 노력이 이를 견인했습니다. 특허 만료에 앞서 매출원을 다각화하려는 회사의 전략과 탄탄한 재무 관리가 투자자 신뢰를 높였습니다. 또한 기술적 지표들은 BMY에 대한 잠재적 매수 신호 가능성도 시사합니다.
테바 제약 USA 주식회사는 엘리 릴리 앤드 컴퍼니를 상대로 한 계약 위반 청구를 성공적으로 다시 제기했습니다. 제7순회 연방항소법원은 테바가 릴리가 테바의 이전 특허 소송에서 나온 합의(릴리의 골다공증 약 포르테오의 제네릭 버전 관련)에 위반했다는 그럴듯한 주장을 제시했다고 판단했으며, 이는 하급심의 기각 결정을 뒤집은 것입니다. 핵심 쟁점은, 정착(합의)에서는 만료 시점을 명시하지 않았는데도 지방법원이 소장 제기 단계에서 포르테오 특허와 함께 합의가 필연적으로 만료됐다고 결론 내린 오류였습니다.
미국 FDA는 아이스아이(Eisai)와 바이오젠(Biogen)의 알츠하이머 약인 르켐비(Leqembi)에 대해 가정에서 투여할 수 있는 초기 용량을 승인했으며, 일부 환자들이 자가 주사로 치료를 시작할 수 있게 됐습니다. 르켐비 IQLIK이라는 브랜드로 불리는 이 피하 제형은 환자 접근성을 높이고 경쟁사들과의 차별화를 기대할 수 있습니다. 이번 승인은 정맥 투여 제형의 이전 임상시험에 근거했으며, 초기 알츠하이머병에서 효과가 확인됐습니다.
이 기사는 State Street Health Care Select Sector SPDR ETF(XLV)의 투자 전략, 보유 종목 및 재무 성과를 강조하며 상세한 프로필을 제공합니다. 운용자산(AUM), 배당 수익률, 비용 비율 등 주요 통계를 다루며, 상위 보유 종목과 지역별 노출에 대한 정보도 포함합니다. 또한 XLV의 투자, 배당 및 시장 성과와 관련해 자주 묻는 질문도 다룹니다.
이 글은 2026년 하반기가 시작됨에 따라 신뢰할 수 있는 배당 소득을 원하는 투자자들을 위해 수익률이 높은 3개 종목—노보 노디스크(NVO), 리얼티 인컴(O), 엔터프라이즈 프로덕츠 파트너스(EPD)—을 소개합니다. 노보 노디스크는 3.5%의 수익률을 제공하며 GLP-1 약물 부문에서 점유율을 되찾고 있는 반면, 엔터프라이즈 프로덕츠 파트너스는 중간자산(미드스트림) 에너지 부문에서 원자재 가격 노출이 낮아 5.9%의 수익률을 제공합니다. 리얼티 인컴은 REIT로서 장기간의 증가 이력을 바탕으로 매달 5%의 일관된 배당금을 지급해 소득 의존형 투자자들에게 매력적입니다.
브리스톨-마이어스 스퀴브 컴퍼니(BMY) 주식은 7월 13일에 3.07% 상승했으며, 온콜로지 및 면역학 분야에서의 긍정적 임상 데이터, 성공적인 규제 관련 이정표, 그리고 효과적인 비용 최적화 노력이 이를 견인했습니다. 특허 만료에 앞서 매출원을 다각화하려는 회사의 전략과 탄탄한 재무 관리가 투자자 신뢰를 높였습니다. 또한 기술적 지표들은 BMY에 대한 잠재적 매수 신호 가능성도 시사합니다.
테바 제약 USA 주식회사는 엘리 릴리 앤드 컴퍼니를 상대로 한 계약 위반 청구를 성공적으로 다시 제기했습니다. 제7순회 연방항소법원은 테바가 릴리가 테바의 이전 특허 소송에서 나온 합의(릴리의 골다공증 약 포르테오의 제네릭 버전 관련)에 위반했다는 그럴듯한 주장을 제시했다고 판단했으며, 이는 하급심의 기각 결정을 뒤집은 것입니다. 핵심 쟁점은, 정착(합의)에서는 만료 시점을 명시하지 않았는데도 지방법원이 소장 제기 단계에서 포르테오 특허와 함께 합의가 필연적으로 만료됐다고 결론 내린 오류였습니다.
미국 FDA는 아이스아이(Eisai)와 바이오젠(Biogen)의 알츠하이머 약인 르켐비(Leqembi)에 대해 가정에서 투여할 수 있는 초기 용량을 승인했으며, 일부 환자들이 자가 주사로 치료를 시작할 수 있게 됐습니다. 르켐비 IQLIK이라는 브랜드로 불리는 이 피하 제형은 환자 접근성을 높이고 경쟁사들과의 차별화를 기대할 수 있습니다. 이번 승인은 정맥 투여 제형의 이전 임상시험에 근거했으며, 초기 알츠하이머병에서 효과가 확인됐습니다.
이 기사는 State Street Health Care Select Sector SPDR ETF(XLV)의 투자 전략, 보유 종목 및 재무 성과를 강조하며 상세한 프로필을 제공합니다. 운용자산(AUM), 배당 수익률, 비용 비율 등 주요 통계를 다루며, 상위 보유 종목과 지역별 노출에 대한 정보도 포함합니다. 또한 XLV의 투자, 배당 및 시장 성과와 관련해 자주 묻는 질문도 다룹니다.
Stoke Therapeutics는 토머스 맥컬리 박사를 신임 최고과학책임자(CSO)로 임명했습니다. 맥컬리 박사는 과학적 발견을 임상 프로그램으로 전환하는 데 초점을 두고, R&D 팀을 이끈 25년 이상의 경험을 갖고 있습니다. 그의 새로운 역할에서 그는 Stoke의 과학 전략을 이끌고, 회사의 자체 RNA 의약품 플랫폼을 활용해 파이프라인을 확장할 예정입니다.
웰스 파고 애널리스트 모히트 반살은 Eli Lilly & Co(LLY)에 대해 목표주가 1,280.00달러로 매수(Buy) 등급을 유지했습니다. 이는 애널리스트들 사이의 전반적인 "강력 매수(Strong Buy)" 컨센서스와 일치하며, 평균 목표주가는 1,325.05달러입니다. 긍정적인 애널리스트 평가와 견조한 분기 매출에도 불구하고, LLY에 대한 기업 내부자 심리는 내부자 매도 증가로 인해 부정적입니다.
Eli Lilly and Company(LLY)는 2026년 알츠하이머병 국제학회(AAIC)에서 알츠하이머 치료제인 Kisunla에 대한 새로운 데이터를 발표하고 있습니다. 최근 애널리스트들이 주식을 매수(Buy) 등급으로 상향하고 목표주가를 올렸지만, Eli Lilly 주가는 보합세로 거래되고 있습니다. AAIC에서의 발표는 알츠하이머 시장에서 Kisunla의 경쟁적 위치를 명확히 하는 데 도움이 될 것으로 예상됩니다.
LGT Fund Management Co Ltd. has initiated a new stake in CVS Health Corporation, purchasing 50,850 shares valued at approximately $3.65 million during the first quarter. CVS Health recently increased its quarterly dividend to $0.665 per share, indicating confidence in its financial performance, despite facing legal settlements totaling over $470 million for improper billing and false Medicaid insulin claims. The company reported strong Q1 earnings, surpassing analyst expectations, and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $102.84.
JPMorgan has resumed coverage of Alkermes (NASDAQ:ALKS) with a Neutral rating and a $60.00 price target for December 2027. The firm believes Alkermes is entering a new phase with its focus on the sleep space, including its phase III orexin, alixorexton, and the acquisition of Avadel. While the rare hypersomnia space is competitive, JPMorgan noted that the stock's future performance hinges on the clinical development of alixorexton and other new orexins, as well as the commercial performance of Lumryz.
A recent Lobbying Disclosure Act filing revealed that Eli Lilly and Company (LLY) disclosed $80,000 in lobbying expenditures for Q2 2026, focusing on issues like Alzheimer's, obesity medication, Medicare/Medicaid, and the 340B Program. The article also provides a detailed overview of recent LLY stock activities, including congressional trading, insider transactions, hedge fund movements, and analyst ratings with price targets.
This article compares two ETFs: State Street Health Care Select Sector SPDR ETF (XLV) and Invesco Nasdaq Biotechnology ETF (IBBQ), for investors seeking healthcare exposure. XLV offers broad stability with lower costs and volatility, tracking 60 S&P 500 healthcare stocks, while IBBQ provides concentrated exposure to the biotech subsector with higher historical returns but also higher volatility and expense ratios. The analysis details their respective holdings, expense ratios, dividend yields, performance, and risk metrics to help investors choose based on their risk tolerance and investment goals.
This article compares two healthcare-focused ETFs, iShares U.S. Healthcare ETF (IYH) and VanEck Biotech ETF (BBH), for investors. IYH offers broader exposure to the healthcare sector with 100 holdings and lower volatility, while BBH focuses on fewer biotechnology firms, offering higher growth potential but also greater volatility. The analysis details their costs, performance, risk, and core holdings to help investors decide based on their preferences for stability versus growth.
This article compares two healthcare-focused ETFs: State Street Health Care Select Sector SPDR ETF (XLV) and Invesco Nasdaq Biotechnology ETF (IBBQ). XLV offers broad exposure to the healthcare sector with lower costs and volatility, while IBBQ provides focused exposure to biotechnology with higher historical returns but also higher volatility. The article highlights their differences in expense ratios, holdings, and risk profiles to help investors choose based on their preference for stability versus thematic growth.
This article compares two healthcare-focused ETFs: the State Street Health Care Select Sector SPDR ETF (XLV) and the Invesco Nasdaq Biotechnology ETF (IBBQ). XLV offers broad, stable exposure to the healthcare sector with lower costs and established megacap holdings, while IBBQ provides concentrated, higher-growth potential in the volatile biotechnology sector. Investors must weigh stability and lower costs against higher historical returns and greater risk when choosing between these funds.
Conning Inc. has reduced its stake in Amgen Inc. by 5.4% in the first quarter, selling 5,475 shares but still holding 96,214 shares valued at $33.85 million. Despite Conning's reduction, institutional ownership of Amgen remains high at 76.5%, with several other firms increasing their positions. Amgen also surpassed quarterly expectations with strong EPS and revenue, maintaining an average "Hold" rating from analysts.
Bank of America Securities analysts have maintained bullish ratings on two major healthcare companies. Tim Anderson reiterated a Buy rating for AbbVie (ABBV) with a price target of $276, while Jason Gerberry assigned a Buy rating to Eli Lilly & Co (LLY) with a $1334 price target, both implying potential upside from current levels. Both companies hold a consensus of "Strong Buy" among analysts.
This article summarizes Veradermics' presentation at the Jefferies Global Healthcare Conference 2026, highlighting the significant market opportunity for a new hair loss treatment. The company's oral therapy, VDPHL01, showed positive Phase II/III clinical trial results with high patient satisfaction and a strong safety profile. Veradermics plans to strategically commercialize the product by targeting distinct patient segments and leveraging digital acquisition strategies, aiming to address the substantial unmet need in the hair loss market.
Tampa General Hospital (TGH) has filed a lawsuit against Eli Lilly over the pharmaceutical company's decision to roll back drug discounts. This action, reportedly the first of its kind in the nation, came after Eli Lilly discontinued discounts for healthcare providers who did not share specific data. As a result, TGH patients, particularly those using osteoporosis medication Forteo, will experience significant price increases.
Arrowhead Pharmaceuticals Inc. (ARWR) stock fell by 7.27% on July 10, driven by investor concerns about its late-stage clinical pipeline, intensified competition in RNAi therapeutics, and potential equity dilution. The company reported annual revenue of $829.45 million and a net loss of $1.63 million, with technical indicators showing mixed signals (MACD buy, RSI neutral, Williams %R buy). Analysts have an average price target of $90.90 for ARWR, despite risks like loss of long-term asset value due to a royalty agreement, high operational cash burn, and concentrated clinical risk.
This article compares two iShares healthcare ETFs, IHE (U.S. Pharmaceuticals) and IBB (Biotechnology), to help investors decide which is a better fit for their portfolio. IHE offers a lower expense ratio, higher dividend yield, and less volatility, focusing on established pharmaceutical companies. IBB provides broader diversification across the biotech landscape and caters to investors seeking higher growth potential with increased risk.
Gilead Sciences Inc (GILD) stock fell by 3.26% on July 10, primarily due to the failure of a Phase 3 solid tumor clinical trial and broader macroeconomic pressures. Strong employment data contributed to increased Treasury yields, negatively impacting biotech valuations. Analysts are expected to lower earnings forecasts, adding to investor uncertainty despite Gilead's strong HIV franchise.
Johnson & Johnson (JNJ) stock has surged over 71% in the past year, outperforming the S&P 500, driven by strong operating margins, revenue growth, and a promising pipeline of new drugs like ICOTYDE. However, its premium valuation, evidenced by high P/E and P/S ratios, and some weakness in its MedTech division, particularly the Surgery business, suggest that the current price might already factor in much of its future success. The key for continued growth will be the rapid market adoption and revenue generation from new products to offset challenges like biosimilar competition for established blockbusters like STELARA.
Merck & Co. stock (MRK) stands as a major pharmaceutical presence in the S&P 500, offering a diversified portfolio of oncology and vaccine products that drive long-term earnings. The company balances innovation with patent expiry challenges, investing heavily in R&D and strategic acquisitions to maintain its market position. Its role in global health and consistent dividend payments make it an attractive holding for investors seeking defensive characteristics and exposure to medical innovation.
Moderna, ImmunityBio, and Sarepta Therapeutics experienced significant declines of 11% and 8% respectively, marking a broad biotech sector pullback. This selloff is attributed to profit-taking and sector rotation after extraordinary year-to-date gains, with no specific negative company news. The sector-wide drop is evidenced by the SPDR S&P Biotech ETF (XBI) falling 4%, indicating a shift from high-beta biotech stocks to more defensive large-cap pharmaceutical companies.
B. Riley Securities has reiterated LifeMD Inc. (NASDAQ: LFMD) as its top digital health stock to buy, maintaining a Buy rating and a $10 price target. The firm sees the recent sell-off as a buying opportunity, citing new catalysts including a telehealth collaboration with Antares, Medicare coverage for GLP-1 medications, and potential high-margin revenue from an FDA committee meeting. LifeMD also reported strong Q1 2026 financial results, surpassing analyst forecasts.
Mesoblast Limited announced strong Ryoncil net revenue, reaching US$36 million in Q4 FY26 and US$115 million for the full fiscal year, exceeding projections due to high U.S. pediatric demand. CEO Dr. Silviu Itescu confirmed the company's robust capital position, fueled by revenue growth and new financing, which will support strategic initiatives like label extensions and further product development. Ryoncil is the only FDA-approved treatment for children under age 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD), with development ongoing for additional inflammatory diseases and the rexlemestrocel-L platform for heart failure.
Denali Therapeutics will deliver the opening plenary address at the Alzheimer’s Association International Conference (AAIC) 2026, with CEO Ryan Watts discussing advancements in treating neurodegenerative diseases, particularly Alzheimer's. The company will highlight its proprietary TransportVehicle™ platform, which enables biologic therapies to cross the blood-brain barrier. Denali is also developing investigational therapies DNL628 and DNL921 targeting tau and amyloid beta, respectively, with clinical data expected in 2027.
This article compares the Invesco Pharmaceuticals ETF (PJP) and the State Street SPDR S&P Biotech ETF (XBI) for investors seeking healthcare exposure. PJP offers a less volatile, concentrated pharmaceutical focus with a higher dividend yield, while XBI provides high-growth, equal-weighted biotechnology exposure at a lower cost, featuring significant small-cap stock representation. The article concludes that XBI is the better buy due to its long-term performance, despite its higher volatility and past maximum drawdown.
Goldman Sachs Asset Management has been appointed as the outsourced CIO for Verizon Communications Inc. and Lockheed Martin Corp.'s retirement plans, securing a combined $70 billion in mandates. This move reflects a growing trend among plan sponsors to outsource investment management for their pension plans, especially after years of funding surpluses. Goldman Sachs has recently secured several other large OCIO mandates, reinforcing its position in providing customized investment solutions for major retirement plans.
This page provides news and articles related to the Roundhill GLP-1 & Weight Loss ETF (OZEM). It features current stock data for OZEM and highlights an article discussing two major drugmakers dominating the obesity market and how one fund invests in both. The page also includes other financial articles, primarily focused on personal finance topics like mortgage payments and pension planning.
This article examines investment options for capitalizing on the booming GLP-1 obesity drug market, dominated by Eli Lilly and Novo Nordisk. While the broad Health Care Select Sector SPDR Fund (XLV) offers diluted exposure, the specialized LeaderShares Dr. Bill Grace Global Obesity ETF (OZEM) provides more concentrated holdings in these key drugmakers. However, direct investment in companies like Eli Lilly has significantly outperformed both ETFs, highlighting trade-offs between diversification and focused growth.
Lockheed Martin and Verizon have hired Goldman Sachs Asset Management as an outsourced CIO for their retirement plans, transferring a combined $70 billion in defined benefit and defined contribution assets. This move follows a trend of plan sponsors outsourcing pension plan management and previous pension risk transfers by both companies. Goldman Sachs expects this trend to continue as large plan sponsors consolidate responsibilities with expert partners.
Eli Lilly's GLP-1 weight-loss drugs are experiencing massive demand, with U.S. adoption nearly tripling in two years to 11%. This surge has propelled Lilly's market value past $1 trillion and its stock up over 400% in five years, driven by the success of Mounjaro and Zepbound, and the recent launch of its oral GLP-1 therapy, Foundayo. The company increased its 2026 revenue guidance, despite a premium valuation and growing competitive pressure, as the obesity drug market is projected to reach $100 billion by 2030.
Goldman Sachs Asset Management has been selected by Verizon Communications Inc. and Lockheed Martin Corp. to manage their retirement plans, securing a combined $70 billion in new outsourced CIO (OCIO) mandates. These agreements involve $30 billion in defined benefit assets and $40 billion in defined contribution assets. This decision comes as both companies have been actively offloading pension liabilities through risk transfers and reflects a broader trend of plan sponsors outsourcing investment management.
Viking Therapeutics (VKTX) is increasingly seen as a potential acquisition target due to its expanding obesity franchise, particularly with its lead candidate VK2735 and the addition of VK3019. The company is poised for a significant catalyst with upcoming data readouts from a maintenance dosing study on VK2735. The ongoing speculation is fueled by the rapid growth of the obesity market, attracting interest from large pharmaceutical companies looking to strengthen their pipelines.
Sam’s Club and Weight Watchers have partnered to offer wellness benefits to Sam's Club members. Sam’s Club Plus members can receive a complimentary three-month Weight Watchers Core membership, with ongoing access for $10 per month, while all Sam’s Club members qualify for up to 50% off select WW programs like Core+ and Med+. This collaboration aims to provide affordable and comprehensive wellness experiences, including support for those using GLP-1 weight loss medications, by integrating nutrition guidance, healthy food access, and pharmacy services.
The active healthcare ETF GDOC received a boost from positive news surrounding its largest holding, Eli Lilly (LLY). JPMorgan raised its price target for Eli Lilly, contributing to GDOC's recent 11.8% return over three months. The ETF, which actively invests in companies driving innovation in healthcare, is well-positioned for a strong second half, potentially benefiting from future interest rate cuts and increased M&A activity.
Adial Pharmaceuticals (ADIL) focuses on developing therapeutics for addiction, with its lead product AD04 targeting Alcohol Use Disorder. The company faces significant risks including volatile share price, projected earnings decline, shareholder dilution, and minimal revenue. Recent developments include securing substantial funding, a utility patent application for AD04, and submissions to the FDA, alongside a volatile stock performance and several Nasdaq non-compliance notices solved by reverse stock splits and follow-on equity offerings.
Vertex Pharmaceuticals acquired Crinetics for $10 billion, marking the largest deal in its history and entering the specialty endocrinology market. Meanwhile, IPOs and venture capital raises, particularly for derisked companies, saw an upward trend, with Isomorphic Labs securing a $2.1 billion raise. Despite leadership turnover, the FDA's decision pace remained steady in the first half of the year, with expectations for an increase in the second half.
Pfizer (PFE) has gained renewed attention following FDA approval for a new maintenance use of IBRANCE in certain metastatic breast cancer cases and the declaration of a third-quarter dividend. Despite recent stock price weakness, the company is seen as 18% undervalued with a narrative fair value of $29.19, driven by its robust late-stage pipeline in oncology and rare diseases. However, this positive outlook is tempered by policy and patent risks, including potential drug pricing reforms and an approaching patent cliff.
Tampa General Hospital has filed a lawsuit against Eli Lilly and Company, alleging "unconscionable and immoral" rescission of its 340B drug discounts. The hospital, which claims to be spending significantly more on Lilly products, contends that the drugmaker's policy requiring claims-level data imposes an undue administrative burden and violates Florida trade practices laws, while Lilly argues the policy combats fraud and abuse within the 340B program.
This article highlights several companies that experienced significant stock movements yesterday. Carlisle, Rivian, and Blink Charging saw declines due to concerns over rising costs, a share offering, and a Nasdaq compliance issue, respectively. Conversely, Genpact and Eli Lilly experienced gains following a new partnership and an analyst's price target increase.
This article identifies nine healthcare stocks that experienced notable "whale" activity in their options trading sessions. It details specific bullish or bearish call and put option sweeps and trades, including strike prices, expiration dates, and total trade values for companies like Mesoblast, Danaher, and Eli Lilly. The purpose of tracking this activity is to help traders identify potential significant movements or mispricings in options.
Citi has added Micron Technology (MU) to its upside Catalyst Watch due to expectations of significantly stronger DRAM pricing in the second half of 2026, with prices potentially tripling next year. This favorable outlook, coupled with Micron's recent strong Q2 CY2026 revenue and strategic partnerships with General Motors and Ford, suggests continued growth potential for the stock despite its recent rally. Analysts maintain a "Strong Buy" rating with a high average price target, indicating confidence in Micron's ongoing performance.
Nurix Therapeutics is set to report its second-quarter results, with analysts expecting a significant sequential revenue increase driven by its partnership with Roche. Investors will focus on the financial impact of the $700 million upfront payment from the Roche deal and the clinical progress of bexobrutideg, including the planned Phase 3 trial. The report will also shed light on cash burn and operating expense guidance, crucial for investor confidence in the company's future plans.
While Wall Street analysts are raising price targets for Eli Lilly based on the strong performance and potential of its GLP-1 drugs for diabetes and obesity, the article contends they are overlooking a more significant, long-term opportunity. Eli Lilly's investments in an AI-powered drug discovery platform, quietly funded by GLP-1 cash flows and partnered with companies like Nvidia, represent a $1 trillion opportunity that is not yet fully priced into the stock. This AI-biology engine, leveraging decades of proprietary clinical data, could transform drug development and position Lilly for substantial future growth beyond its current metabolic medicine dominance.
Addex Therapeutics announced the publication of research in the Journal of Neuroscience by Professor Thomas Klausberger's group, demonstrating the potential of mGlu7 receptors in regulating sleep and wakefulness. The study, conducted in collaboration with Addex, showed that mGlu7 receptors modulate specific neurophysiological activities associated with arousal and sleep, suggesting a novel therapeutic target for sleep disorders and other central nervous system conditions. Addex plans to continue exploring selective mGlu7 modulators for these indications.
The weight loss drug market, propelled by GLP-1 therapies, is projected to reach $130-150 billion by 2035. The Amplify Weight Loss Drug & Treatment ETF (THNR) provides investors with targeted exposure to this expanding sector, including pharmaceutical giants like Novo Nordisk and Eli Lilly, and is expected to grow further with innovations like oral drugs and genetic treatments. Despite a recent slowdown in prescriptions for Novo Nordisk's oral Wegovy, UBS favors European pharma, citing resilience and growth particularly driven by weight-loss drugs.
This article highlights several companies that experienced significant stock movements yesterday. Carlisle, Rivian, and Blink Charging saw declines due to concerns over rising costs, plans to sell shares, and compliance issues, respectively. In contrast, Genpact rose after announcing a partnership with Nestlé, and Eli Lilly also increased following an analyst's price target raise.
